Agile Therapeutics, Inc.
AGRX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | -0.06 |
| FCF Yield | -227.72% | -735.47% | -5,528.30% | -19.61% |
| EV / EBITDA | -0.19 | -0.05 | 0.00 | -5.06 |
| Quality | ||||
| ROIC | 235.31% | -1,198.90% | -266.57% | -78.40% |
| Gross Margin | 54.18% | 37.19% | -161.35% | 62.35% |
| Cash Conversion Ratio | 0.66 | 1.41 | 0.87 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 68.42% | 144.03% | – | – |
| Free Cash Flow Growth | 73.46% | 44.89% | -37.36% | -201.92% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | 0.08 | 0.02 | -0.04 |
| Interest Coverage | -14.01 | -13.23 | -18.14 | -15.78 |
| Efficiency | ||||
| Inventory Turnover | 3.28 | 5.13 | 11.10 | 0.00 |
| Cash Conversion Cycle | -214.73 | -228.58 | -127.18 | -4,583.63 |